.jpg "Agenus (NASDAQ: AGEN)")
In a report released yesterday, Matt Phipps from William Blair maintained a Buy rating on Agenus (AGEN). The company’s shares closed last Tuesday at $4.23.
According to TipRanks.com, Phipps is a 1-star analyst with an average return of -1.9% and a 43.6% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Pieris Pharmaceuticals, and Atara Biotherapeutics.
Agenus has an analyst consensus of Strong Buy, with a price target consensus of $8.00, representing a 68.8% upside. In a report issued on September 18, Jefferies also maintained a Buy rating on the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
Based on Agenus’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $26.95 million and GAAP net loss of $47.48 million. In comparison, last year the company earned revenue of $15.72 million and had a GAAP net loss of $50.63 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.
Read More on AGEN:
